{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T11:58:23Z","timestamp":1781351903692,"version":"3.54.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,13]]},"DOI":"10.7759\/cureus.110775","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T11:34:41Z","timestamp":1781350481000},"source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic Efficacy of Anti-Interleukin-5 Monoclonal Antibodies in Kimura Disease: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Sylwia","family":"Olizarowicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Mierzejewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Majewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Szczepanska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/genes16020194","article-title":"Narrative review of genetic and immunological mechanisms involved in the pathogenesis of Kimura's disease: New therapeutic targets","volume":"16","author":"Loperfido A","year":"2025","unstructured":"Loperfido A, Cavaliere C, Fionda B, Bellocchi G, Masieri S, Caminati M. Narrative review of genetic and immunological mechanisms involved in the pathogenesis of Kimura's disease: New therapeutic targets. Genes (Basel). 2025, 16:194. 10.3390\/genes16020194","journal-title":"Genes (Basel)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200404000-00010","article-title":"Kimura disease: A clinicopathologic study of 21 cases","volume":"28","author":"Chen H","year":"2004","unstructured":"Chen H, Thompson LD, Aguilera NS, Abbondanzo SL. Kimura disease: A clinicopathologic study of 21 cases. Am J Surg Pathol. 2004, 28:505-13. 10.1097\/00000478-200404000-00010","journal-title":"Am J Surg Pathol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5414\/CNCS111774","article-title":"Membranous nephropathy in Kimura disease: A case report and literature review on renal biopsy findings","volume":"13","author":"Murata M","year":"2025","unstructured":"Murata M, Koga K, Yamaoka S, Hasebe M, Fukushima C, Omiya C, Yahata K. Membranous nephropathy in Kimura disease: A case report and literature review on renal biopsy findings. Clin Nephrol Case Stud. 2025, 13:96-102. 10.5414\/CNCS111774","journal-title":"Clin Nephrol Case Stud"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-022-02378-y","article-title":"Kimura's disease successively affecting multiple body parts: A case-based literature review","volume":"22","author":"Yang B","year":"2022","unstructured":"Yang B, Liao H, Wang M, et al.. Kimura's disease successively affecting multiple body parts: A case-based literature review. BMC Ophthalmol. 2022, 22:154. 10.1186\/s12886-022-02378-y","journal-title":"BMC Ophthalmol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s12105-025-01812-z","article-title":"A comprehensive review of Kimura disease","volume":"19","author":"Lagerstrom IT","year":"2025","unstructured":"Lagerstrom IT, Danielson DT, Muir JM, Foss RD, Auerbach A, Aguilera NS. A comprehensive review of Kimura disease. Head Neck Pathol. 2025, 19:75. 10.1007\/s12105-025-01812-z","journal-title":"Head Neck Pathol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12880-025-01618-z","article-title":"A stepwise decision tree model for differential diagnosis of Kimura's disease in the head and neck","volume":"25","author":"Luo R","year":"2025","unstructured":"Luo R, Yang G, Shi H, He Y, Han Y, Tian Z, Wu Y. A stepwise decision tree model for differential diagnosis of Kimura's disease in the head and neck. BMC Med Imaging. 2025, 25:90. 10.1186\/s12880-025-01618-z","journal-title":"BMC Med Imaging"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-198903000-00001","article-title":"Lymphadenopathy of Kimura's disease","volume":"13","author":"Hui PK","year":"1989","unstructured":"Hui PK, Chan JK, Ng CS, Kung IT, Gwi E. Lymphadenopathy of Kimura's disease. Am J Surg Pathol. 1989, 13:177-86. 10.1097\/00000478-198903000-00001","journal-title":"Am J Surg Pathol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.5858\/2007-131-650-KD","article-title":"Kimura disease","volume":"131","author":"Abuel-Haija M","year":"2007","unstructured":"Abuel-Haija M, Hurford MT. Kimura disease. Arch Pathol Lab Med. 2007, 131:650-1. 10.5858\/2007-131-650-KD","journal-title":"Arch Pathol Lab Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2022.106591","article-title":"Treatment algorithm for Kimura's disease: A systematic review and meta-analysis of treatment modalities and prognostic predictors","volume":"100","author":"Lee CC","year":"2022","unstructured":"Lee CC, Feng IJ, Chen YT, et al.. Treatment algorithm for Kimura's disease: A systematic review and meta-analysis of treatment modalities and prognostic predictors. Int J Surg. 2022, 100:106591. 10.1016\/j.ijsu.2022.106591","journal-title":"Int J Surg"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2449153","article-title":"Successful treatment of Kimura's disease with dupilumab and review of dupilumab in treating eosinophilic dermatoses","volume":"36","author":"Zheng Y","year":"2025","unstructured":"Zheng Y, Luo S. Successful treatment of Kimura's disease with dupilumab and review of dupilumab in treating eosinophilic dermatoses. J Dermatolog Treat. 2025, 36:2449153. 10.1080\/09546634.2024.2449153","journal-title":"J Dermatolog Treat"},{"key":"ref11","article-title":"Novel therapeutic approaches in Kimura disease: The role of omalizumab","volume":"3","author":"Zolfagharimoheb V","year":"2025","unstructured":"Zolfagharimoheb V, Nabih J, Alvandi S, Vu C, Al-Maini MH. Novel therapeutic approaches in Kimura disease: The role of omalizumab. Int J Allergy Immunol. 2025, 3:1-4.","journal-title":"Int J Allergy Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400732","article-title":"IL-5 triggers a cooperative cytokine network that promotes eosinophil precursor maturation","volume":"193","author":"Fulkerson PC","year":"2014","unstructured":"Fulkerson PC, Schollaert KL, Bouffi C, Rothenberg ME. IL-5 triggers a cooperative cytokine network that promotes eosinophil precursor maturation. J Immunol. 2014, 193:4043-52. 10.4049\/jimmunol.1400732","journal-title":"J Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010834.pub3","article-title":"Anti-IL5 therapies for asthma","volume":"9","author":"Farne HA","year":"2017","unstructured":"Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017, 9:CD010834. 10.1002\/14651858.CD010834.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.46658\/JBIMES-24-06","article-title":"Chapter 7: Systematic reviews of etiology and risk","author":"Moola S","year":"2020","unstructured":"Moola S, Munn Z, Tufanaru C, et al.. Chapter 7: Systematic reviews of etiology and risk. JBI Manual for Evidence Synthesis. Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan Z (ed): JBI, South Australia; 2020. 10.46658\/JBIMES-24-06"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.11124\/JBISRIR-D-19-00099","article-title":"Methodological quality of case series studies: An introduction to the JBI critical appraisal tool","volume":"18","author":"Munn Z","year":"2020","unstructured":"Munn Z, Barker TH, Moola S, et al.. Methodological quality of case series studies: An introduction to the JBI critical appraisal tool. JBI Evid Synth. 2020, 18:2127-33. 10.11124\/JBISRIR-D-19-00099","journal-title":"JBI Evid Synth"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-232627","article-title":"Eosinophilic chronic rhinosinusitis and concurrent Kimura's disease treated with mepolizumab","volume":"14","author":"Ho J","year":"2021","unstructured":"Ho J, Walter S, Harvey RJ. Eosinophilic chronic rhinosinusitis and concurrent Kimura's disease treated with mepolizumab. BMJ Case Rep. 2021, 14:e232627. 10.1136\/bcr-2019-232627","journal-title":"BMJ Case Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.02.049","article-title":"Mepolizumab-responsive Kimura disease","volume":"9","author":"Kinoshita M","year":"2021","unstructured":"Kinoshita M, Ogawa Y, Onaka M, Shimada S, Kawamura T. Mepolizumab-responsive Kimura disease. J Allergy Clin Immunol Pract. 2021, 9:2928-30. 10.1016\/j.jaip.2021.02.049","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_373_19","article-title":"Mepolizumab as an effective treatment for Kimura's disease associated with ulcerative colitis: A case report","volume":"8","author":"Al Shammari F","year":"2019","unstructured":"Al Shammari F, Nasiri A, Alkhathami M, Alawfi F, Alfifi M, Al Otaibi E. Mepolizumab as an effective treatment for Kimura's disease associated with ulcerative colitis: A case report. J Family Med Prim Care. 2019, 8:3028-31. 10.4103\/jfmpc.jfmpc_373_19","journal-title":"J Family Med Prim Care"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2025.2486668","article-title":"Rapid improvement of Kimura disease with dupilumab in a patient with suboptimal response to mepolizumab: A case report","volume":"36","author":"Tao M","year":"2025","unstructured":"Tao M, Gao T, Zhi L, Cao N, Liu H. Rapid improvement of Kimura disease with dupilumab in a patient with suboptimal response to mepolizumab: A case report. J Dermatolog Treat. 2025, 36:2486668. 10.1080\/09546634.2025.2486668","journal-title":"J Dermatolog Treat"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S538560","article-title":"Kimura disease: Retrospective analysis of 53 cases and three mepolizumab-responsive cases","volume":"18","author":"Zhu W","year":"2025","unstructured":"Zhu W, Zhang L, Zhang J, et al.. Kimura disease: Retrospective analysis of 53 cases and three mepolizumab-responsive cases. J Inflamm Res. 2025, 18:13773-85. 10.2147\/JIR.S538560","journal-title":"J Inflamm Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.71275","article-title":"Kimura disease with eosinophilic granulomatosis with polyangiitis successfully treated by mepolizumab","volume":"13","author":"Du W","year":"2025","unstructured":"Du W, Dai R, Chen X, Tang W. Kimura disease with eosinophilic granulomatosis with polyangiitis successfully treated by mepolizumab. Clin Case Rep. 2025, 13:e71275. 10.1002\/ccr3.71275","journal-title":"Clin Case Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.radcr.2025.04.060","article-title":"Kimura disease and eosinophilic granulomatosis with polyangiitis: Clinical and imaging overlap of 2 immune-mediated conditions","volume":"20","author":"Yoon WY","year":"2025","unstructured":"Yoon WY, Shaar BA, Lee AC, Holsinger C, Martin B, Chung SA, Fischbein N. Kimura disease and eosinophilic granulomatosis with polyangiitis: Clinical and imaging overlap of 2 immune-mediated conditions. Radiol Case Rep. 2025, 20:3632-8. 10.1016\/j.radcr.2025.04.060","journal-title":"Radiol Case Rep"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04873-0","article-title":"Successful treatment of Kimura disease with benralizumab","volume":"101","author":"Szeto VG","year":"2022","unstructured":"Szeto VG, Chin-Yee B, Dehghani M, Rizkalla K, Licskai C, Hsia CC. Successful treatment of Kimura disease with benralizumab. Ann Hematol. 2022, 101:2099-100. 10.1007\/s00277-022-04873-0","journal-title":"Ann Hematol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1702989","article-title":"Benralizumab for adults with rare and off-label eosinophilic disorders: A 52-week prospective, single-center study","volume":"16","author":"Talmon A","year":"2025","unstructured":"Talmon A, Shamriz O, Rubin L, et al.. Benralizumab for adults with rare and off-label eosinophilic disorders: A 52-week prospective, single-center study. Front Immunol. 2025, 16:1702989. 10.3389\/fimmu.2025.1702989","journal-title":"Front Immunol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/SCS.0000000000002337","article-title":"Comparison of local recurrence rate of three treatment modalities for Kimura disease","volume":"27","author":"Ye P","year":"2016","unstructured":"Ye P, Wei T, Yu GY, Wu LL, Peng X. Comparison of local recurrence rate of three treatment modalities for Kimura disease. J Craniofac Surg. 2016, 27:170-4. 10.1097\/SCS.0000000000002337","journal-title":"J Craniofac Surg"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2183\/pjab.87.463","article-title":"Interleukin-5 and IL-5 receptor in health and diseases","volume":"87","author":"Takatsu K","year":"2011","unstructured":"Takatsu K. Interleukin-5 and IL-5 receptor in health and diseases. Proc Jpn Acad Ser B Phys Biol Sci. 2011, 87:463-85. 10.2183\/pjab.87.463","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/all.16346","article-title":"Targeting the IL-5 pathway in eosinophilic asthma: A comparison of anti-IL-5 versus anti-IL-5 receptor agents","volume":"79","author":"Jackson DJ","year":"2024","unstructured":"Jackson DJ, Wechsler ME, Brusselle G, Buhl R. Targeting the IL-5 pathway in eosinophilic asthma: A comparison of anti-IL-5 versus anti-IL-5 receptor agents. Allergy. 2024, 79:2943-52. 10.1111\/all.16346","journal-title":"Allergy"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler ME","year":"2017","unstructured":"Wechsler ME, Akuthota P, Jayne D, et al.. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017, 376:1921-32. 10.1056\/NEJMoa1702079","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.08.037","article-title":"Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A\u00a0phase III, randomized, placebo-controlled trial","volume":"146","author":"Roufosse F","year":"2020","unstructured":"Roufosse F, Kahn JE, Rothenberg ME, et al.. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A\u00a0phase III, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020, 146:1397-405. 10.1016\/j.jaci.2020.08.037","journal-title":"J Allergy Clin Immunol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A\u00a0randomized, placebo-controlled trial","volume":"149","author":"Bachert C","year":"2022","unstructured":"Bachert C, Han JK, Desrosiers MY, et al.. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A\u00a0randomized, placebo-controlled trial. J Allergy Clin Immunol. 2022, 149:1309-1317.e12. 10.1016\/j.jaci.2021.08.030","journal-title":"J Allergy Clin Immunol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: Results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro M","year":"2015","unstructured":"Castro M, Zangrilli J, Wechsler ME, et al.. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: Results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015, 3:355-66. 10.1016\/S2213-2600(15)00042-9","journal-title":"Lancet Respir Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.07.038","article-title":"Safety of reslizumab in uncontrolled asthma with eosinophilia: A pooled analysis from 6 trials","volume":"8","author":"Virchow JC","year":"2020","unstructured":"Virchow JC, Katial R, Brusselle GG, Shalit Y, Garin M, McDonald M, Castro M. Safety of reslizumab in uncontrolled asthma with eosinophilia: A pooled analysis from 6 trials. J Allergy Clin Immunol Pract. 2020, 8:540-548.e1. 10.1016\/j.jaip.2019.07.038","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30406-5","article-title":"Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial","volume":"7","author":"Busse WW","year":"2019","unstructured":"Busse WW, Bleecker ER, FitzGerald JM, et al.. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019, 7:46-59. 10.1016\/S2213-2600(18)30406-5","journal-title":"Lancet Respir Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/500782-therapeutic-efficacy-of-anti-interleukin-5-monoclonal-antibodies-in-kimura-disease-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T11:34:42Z","timestamp":1781350482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/500782-therapeutic-efficacy-of-anti-interleukin-5-monoclonal-antibodies-in-kimura-disease-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7759\/cureus.110775","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,13]]}}}